In a murine model of atherosclerosis, chronic administration of FTY720 and S1PR1-selective agonists reduced atherosclerotic lesions12,13,39,40, and a more recent study41 showed that endothelial-specific genetic deletion of S1pr1 exacerbated atherosclerosis, indicating that endothelial S1PR1 limits atherosclerosis. This evidence concerns the gene S1PR1 and atherosclerosis.